ClinicalTrials.gg
CompletedNCT01145625Updated May 22, 2014Results posted

Clinical Trial in Females With Female Pattern Hair Loss

A Phase 3 interventional study of 5% Minoxidil and 2% Minoxidil in Alopecia, sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.. Completed at 12 sites in 5 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-22.

Sponsored by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc. (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
322
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing minoxidil in Alopecia — 10 open to participants now, 12 under way, 3 of them phase 3. Minoxidil · Alopecia.

Enrollment
4th of 31
322 · median 60
Started
2010
with 1 other
Phase 3
8 of 31
2 open now
Registered
4th of 31
by date

Among the 31 studies testing minoxidil in Alopecia, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 3, and was the 4th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

10 of the 31 studies testing minoxidil in Alopecia are open now, in 5 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About minoxidil

Minoxidil: first FDA approval 1979 (LONITEN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing minoxidil in Alopecia, or all of them as a file.
02

Study summary

This is a year-long clinical trial to evaluate the effectiveness and safety in women with Female Pattern Hair Loss (FPHL), comparing a new 5% minoxidil topical foam (MTF) formulation applied once a day versus the 2% minoxidil topical solution (MTS) applied twice a day.

This clinical trial uses an objective measurement called Target Area Hair Count (TAHC) to evaluate if there is a change in the number of hairs in the area being examined after using the product for 24 weeks (and also after using the product for 12 Weeks and for 52 weeks).

This trial will determine if the benefit of using either study product outweighs the risks.

Read the detailed description

This is a phase 3, two-arm, randomized, active-controlled, multi-center, 52-week, parallel design trial to evaluate the efficacy and safety in women with Female Pattern Hair Loss (FPHL), comparing the new 5% minoxidil topical foam (MTF) formulation versus the 2% minoxidil topical solution (MTS) formulation.

This clinical trial is designed to compare the risk/benefit profile of the 5% MTF formulation applied once a day versus the 2% MTS applied twice a day (BID), using objective efficacy measures and safety assessments.

Study centers will screen a sufficient number of participants so that a minimum of 300 female participants with FPHL will be enrolled, to ensure 270 to complete. There will be at least 16 participants enrolled per center at multiple centers located across the US and globally. Approximately 300 participants will be randomly assigned in a 1:1 ratio to use either 5% MTF or 2% MTS, for 52 weeks for efficacy and safety evaluations.

Participants meeting the inclusion criteria will be randomly assigned in the order of their enrollment at each site. The signing of the informed consent and assignment of a participant number to a subject shall constitute enrollment.

During the trial following enrollment at Baseline, participants will return to the study site at regular intervals for safety assessments, adverse events monitoring, and compliance assessments. At the Week 12, 24, and Week 52 visits TAHC will be evaluated for efficacy analysis.

03

Conditions studied

  • Alopecia

Browse trials for

Keywords

  • Female Pattern Baldness
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • females, age 18 or older in general good health
  • exhibits female pattern hair loss
  • signs and dates an document
  • agrees to use an adequate method of ; if of
  • shows a negative urine pregnancy test at Screening Visit
  • is willing to maintain the same hair style, hair color, and hair regimen throughout the study
  • is willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures

Exclusion criteria

Exclusion Criteria:

  • to the study product, or any ingredients of the study product
  • known allergy to hair dye, or hair dye components
  • history of hypotension
  • untreated or uncontrolled hypertension
  • pregnant, planning a pregnancy or nursing a child
  • history of hair transplants
  • currently use hair weaves or non-breathable wigs
  • dermatologic disorders of the scalp that require chronic use of medication for control
  • other types or history of hair loss
  • enrolled in any other medication (drug) study currently, or within the last 6 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
322 participants (actual)

Study arms

  • Experimental
    5% MTF

    5% Minoxidil Topical Foam

    Drug: 5% Minoxidil

  • Active comparator
    2% MTS

    2% Minoxidil Topical Solution

    Drug: 2% Minoxidil

Interventions

  • half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks

  • one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks

    Also known as: ROGAINE®

06

What researchers measure

Primary outcomes

  1. Target Area Hair Count (TAHC)

    Number of hairs in the area being examined as measured by macrophotography.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Target Area Hair Count (TAHC)

    Number of hairs in the area being examined as measured by macrophotography

    Time frame: Baseline to Week 12

Other outcomes

  1. Target Area Hair Count (TAHC)

    Number of hairs in the area being examined as measured by macrophotography.

    Time frame: Baseline to Week 52

07

Results

Posted Apr 25, 2014

Participant flow

Participant flow — Overall Study
Milestone2% MTS5% MTF
Started161161
Completed137130
Not completed2431
Withdrew: Lost to follow-up89
Withdrew: Adverse event64
Withdrew: Protocol violation31
Withdrew: Withdrawal by subject716
Withdrew: Pregnancy01

Outcome measures

PrimaryTarget Area Hair Count (TAHC)

Number of hairs in the area being examined as measured by macrophotography.

Time frame:
Baseline to Week 24
Reported as:
Mean · hairs per centimeter squared
Target Area Hair Count (TAHC)
hairs per centimeter squared2% MTS5% MTF
Baseline167.3 ± 55.0169.7 ± 58.6
Week 24192.8 ± 57.0194.4 ± 64.7
Change from Baseline to Week 2423.8 ± 24.723.7 ± 22.9
Statistical analysis
  • 2% MTS vs 5% MTF · ANCOVA · p = 0.9170 · Mean difference (final values): -0.3 · 95% CI -6.0 to 5.4P-Value and confidence interval are from ANCOVA model with treatment and center as factors and Baseline hair count as a covariate.
SecondaryTarget Area Hair Count (TAHC)

Number of hairs in the area being examined as measured by macrophotography

Time frame:
Baseline to Week 12
Reported as:
Mean · hairs per centimeter squared
Target Area Hair Count (TAHC)
hairs per centimeter squared2% MTS5% MTF
Baseline167.3 ± 55.0169.7 ± 58.6
Week 12190.7 ± 56.9191.8 ± 62.6
Change from Baseline to Week 1222.5 ± 22.824.9 ± 26.0
Statistical analysis
  • 2% MTS vs 5% MTF · ANCOVA · p = <0.4158 · Mean difference (final values): 2.4 · 95% CI -3.4 to 8.2P-Value and confidence interval are from ANCOVA model with treatment and center as factors and Baseline hair count as a covariate.
Other pre-specifiedTarget Area Hair Count (TAHC)

Number of hairs in the area being examined as measured by macrophotography.

Time frame:
Baseline to Week 52
Reported as:
Mean · hairs per centimeter squared
Target Area Hair Count (TAHC)
hairs per centimeter squared2% MTS5% MTF
Baseline167.3 ± 55.0169.7 ± 58.6
Week 52189.1 ± 55.8186.9 ± 61.1
Change from Baseline to Week 5219.4 ± 21.518.1 ± 23.4
Statistical analysis
  • 2% MTS vs 5% MTF · ANCOVA · p = 0.5980 · Mean difference (final values): -1.5 · 95% CI -7.1 to 4.1P-value and confidence interval are from ANCOVA model with treatment and center as factors and Baseline hair count as a covariate.

Adverse events

Non-serious events are listed at a 2.0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2% MTS—8/161 (5%)118/161 (73.3%)
5% MTF—2/161 (1.2%)109/161 (67.7%)
Most frequent serious events
Most frequent serious events
Event2% MTS5% MTF
Anal AbscessInfections and infestations1/1610/161
InfluenzaInfections and infestations1/1610/161
Angina PectorisCardiac disorders1/1610/161
Abdominal PainGastrointestinal disorders1/1610/161
Bile Duct StoneHepatobiliary disorders1/1610/161
Wrist FractureInjury, poisoning and procedural complications0/1611/161
Metastatic NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1610/161
AnxietyPsychiatric disorders0/1611/161
MenometrorrhagiaReproductive system and breast disorders1/1610/161
AsthmaRespiratory, thoracic and mediastinal disorders1/1610/161
Most frequent other events
Showing 10 of 22
Most frequent other events
Event2% MTS5% MTF
NasopharyngitisInfections and infestations22/16123/161
Weight increasedInvestigations14/16120/161
Upper respiratory tract infectionInfections and infestations8/16116/161
HeadacheNervous system disorders16/1619/161
SinusitisInfections and infestations12/16110/161
Urinary tract infectionInfections and infestations3/1618/161
BronchitisInfections and infestations2/1618/161
Back painMusculoskeletal and connective tissue disorders5/1617/161
Procedural painInjury, poisoning and procedural complications6/1614/161
DiarrhoeaGastrointestinal disorders2/1615/161

Baseline characteristics

Intent to Treat (ITT) population defined as all participants randomly assigned to a treatment group who received dispensed investigational product.

Age, Categorical
Age, Categorical(Participants)2% MTS5% MTFTotal
<=18 years112
Between 18 and 65 years134129263
>=65 years263157
Sex: Female, Male
Sex: Female, Male(Participants)2% MTS5% MTFTotal
Female161161322
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2% MTS5% MTFTotal
American Indian or Alaska Native011
Asian4711
Native Hawaiian or Other Pacific Islander011
Black or African American459
White149141290
More than one race000
Unknown or Not Reported4610
08

Study locations

12 sites
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • Oregon Medical Research Center, P.C.
    Portland,, Oregon 97223, United States
  • NW Dermatology and Research Center
    Portland, Oregon 97210, United States
  • DermResearch, Inc
    Austin, Texas 78759, United States
  • Dermatology Research Center, Inc.
    Salt Lake City, Utah 84124, United States
  • The Skin Care Centre
    Vancouver, British Columbia V5Z 4E8, Canada
  • Centre de Santé Sabouraud
    Paris, Île-de-France 75010, France
  • Klinik für Dermatologie, Venerologie und Allergologie, Clinical Research Center for Hair and Skin Science
    Berlin, 10117, Germany
  • Royal Hallamshire Hospital
    Sheffield, South Yorkshire S10 2JF, United Kingdom
09

References and documents

Publications

  • Blume-Peytavi U, Shapiro J, Messenger AG, Hordinsky MK, Zhang P, Quiza C, Doshi U, Olsen EA. Efficacy and Safety of Once-Daily Minoxidil Foam 5% Versus Twice-Daily Minoxidil Solution 2% in Female Pattern Hair Loss: A Phase III, Randomized, Investigator-Blinded Study. J Drugs Dermatol. 2016 Jul 1;15(7):883-9. PubMed 27391640 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 2 years 2 months after primary completion. A results delay was requested in Feb 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2010
First posted
Jun 16, 2010
Start
Jun 2010
Primary completionActual
Feb 2012
CompletionActual
Feb 2012
Results delay requested
Feb 5, 2013
Results first posted
Apr 25, 2014
Last update
May 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01145625
Responsible party
Sponsor
First posted
Jun 16, 2010
Start date
Jun 2010
Primary completion
Feb 2012
Completion
Feb 2012
Results posted
Apr 25, 2014
Last update
May 22, 2014

Study contacts

Clare Kendall, MA
study director · Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Minoxidil

Start the discussion